Atezolizumab 1200 Maintenance, Non-Small Cell Lung Cancer

Protocol-ID: 1272 V1.1 (Complete), ATEZ1200 maint., NSCLC

Indication(s)

- Lung Carcinoma, Non-Small Cell; ICD-10 C34.- non-squamous

Protocol classification

- Classification: current standard
- Intensity: Standard dose
- Therapy mode: First line
- Therapy intention: palliative

Cycles

Cycle length 21 days, recommended cycles: 10

Protocol sequences

- IMpower130: ATEZ1200/NPAC100/CRBP6, NSCLC (PID1238) -|- ATEZ1200 Erh. (PID1272)

Risks

- Emetogenicity (MASCC/ESMO): minimal (<10%)
- Neutropenia: high (21-40%) °3-4: 32%
- Thrombocytopenia below 50 000/µl: very high (>41%) °3-4: 45%
- Anemia Hb below 8g/dl: high (16-30%) °3-4: 29%
- Diarrhea: CTC AE °3-4: 5%
- Fatigue: CTC AE °3-4: 6%
- Nausea: CTC AE °3-4: 3%

Therapy

Hydration: Balanced Crystalloid Solution **HYD**

Access: peripheral venous

Hydration before, during, or after antitumor therapy

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	**Balanced Crystalloid Solution**	500 ml		i.v.	60 min	60 min before Atezolizumab (d1)

Antineoplastic therapy: ATEZ1200 **CTX**

Access: peripheral venous

Atezolizumab in non-small cell, non-plate epithelial lung cancer

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	**Atezolizumab**	1200 mg	NaCl 0.9% 250 ml	i.v.	60 min	Sequence

Substance links

Links to substances are found here.

Notes

Therapy is provided until clinical benefit is diminished or undesirable side effects occur.
The risk data refer to the overall protocol.

Cycle diagram

Hydration: Balanced Crystalloid Solution

	Week 1 / d						
Substance	**1**	**2**	**3**	**4**	**5**	**6**	**7**
Balanced Crystalloid Solution (i.v.)							

Antineoplastic therapy: ATEZ1200

	Week 1 / d						
Substance	**1**	**2**	**3**	**4**	**5**	**6**	**7**
Atezolizumab (i.v.)							

Cycles

Cycle length 21 days, recommended cycles: 10

Controls:

- Blood count: before next cycle
- ECG
- Day 1: Na^+, K^+, Ca^{2+}, Mg^{2+}
- Day 1: Creatinine, glomerular filtration rate (GFR)
- Day 1: GOT, GPT, GGT, Bilirubin, AP, Cholinesterase
- Day 1: Lipase
- Day 1: Troponin T, CK, LDH
- Day 1: TSH, fT4, cortisol basal, blood glucose (HbA1c) optional and especially if clinically suspected: fT3, ACTH, DHEA-S, IGF1, prolactin, LH/FSH, estradiol (in women), every 6 weeks to 3 months after the end of immunotherapy and every 3 months thereafter.
- Day 1: Urine status

Original indication

non-small cell lung cancer, adeno-, stage IV, first line, ECOG 0-1

Original author

West H (2019)

Origin

Thoracic Oncology Program, Swedish Cancer Institute, Seattle, USA, IMpower130

References

- West H, Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. PMID: 31122901. [PMID]

Recommendations

- 01/2023: European Society for Medical Oncology
- 02/2024: National Comprehensive Cancer Network

Status

Valid since 2025-07-08, Version 1.1, last updated 2025-07-08

Last modification: V1.1: Adaptation of protocol title V1.0: Cato test done. V0.1: Runtimes according to summary of product

characteristics.

Important notice